Search
for

    Did you mean Psoriasis Area and Severity Index?
    Glossary Psoriasis Area and Severity Index

    tool measuring psoriasis severity and affected body area

    The Psoriasis Area and Severity Index (PASI) is a tool used by healthcare professionals to measure the severity and extent of psoriasis, a chronic skin condition. It combines the assessment of the redness, thickness, and scaling of the skin lesions with the percentage of body surface area affected, providing a score that helps guide treatment decisions and monitor disease progression.

    Related Terms

    Sort by

    Research 30 of 1000+

    1. Facial Psoriasis Log-based Area and Severity Index: A valid and reliable severity measurement method detecting improvement of facial psoriasis in clinical practice settings The Journal of Dermatology · 2016 · 2 citations
    2. New Topical Treatment for Psoriasis Journal of exploratory research in pharmacology · 2023
    3. Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double‐blinded clinical trial Skin research and technology · 2024 · 1 citations
    4. Wiederbehaarung bei einem Patienten mit Alopecia universalis und Psoriasis vulgaris unter Deucravacitinib‐Therapie JDDG Journal der Deutschen Dermatologischen Gesellschaft · 2025
    5. Impact of ustekinumab on quality of life and sexual difficulties associated with psoriasis: Results from phase III clinical trials Journal of The American Academy of Dermatology · 2010
    6. Dovobet ointment under occlusion overnight for troublesome scalp psoriasis Acta dermato-venereologica · 2006 · 8 citations
    7. Real-world single-center experience with 10 cases of generalized pustular psoriasis successfully treated with ixekizumab Journal of the American Academy of Dermatology · 2019 · 21 citations
    8. Narrowband UVB treatment induces expression of WNT7B, WNT10B and TCF7L2 in psoriasis skin Archives of Dermatological Research · 2019 · 5 citations
    9. Generalized hypertrichosis due to secukinumab in a patient with moderate psoriasis: A case of serendipity or zemblanity? Dermatologic therapy · 2019 · 5 citations
    10. Fluticasone Propionate-loaded Black Cumin Oil NLCs with Dual Deposition/Permeation Capabilities for Enhanced Psoriasis Management Advanced Pharmaceutical Bulletin · 2026
    11. MANAGEMENT OF EKAKUSTHA (PLAQUE PSORIASIS) THROUGH INTEGRATED SHODHANA AND SHAMANA CHIKITSA: A SINGLE CASE STUDY Zenodo (CERN European Organization for Nuclear Research) · 2026
    12. MANAGEMENT OF EKAKUSTHA (PLAQUE PSORIASIS) THROUGH INTEGRATED SHODHANA AND SHAMANA CHIKITSA: A SINGLE CASE STUDY Zenodo (CERN European Organization for Nuclear Research) · 2026
    13. CGF therapy: bridging androgenetic alopecia observations to psoriasis treatment via IL-17 pathway Stem Cell Research & Therapy · 2024
    14. 44047 Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry Journal of the American Academy of Dermatology · 2023
    15. Immune signatures of psoriasis: Comparison of genetic expression profiles in psoriasis patients after therapy with biologic agents Journal of The American Academy of Dermatology · 2015
    16. Videodermoscopy Scalp Psoriasis Severity Index (VSCAPSI): A useful tool for evaluation of scalp psoriasis European Journal of Dermatology · 2011 · 12 citations
    17. Monovalent antibody-conjugated lipid-polymer nanohybrids for active targeting to desmoglein 3 of keratinocytes to attenuate psoriasiform inflammation Theranostics · 2021 · 18 citations
    18. 305 Overlaps between inflammatory dermatoses and ichthyoses: need for novel therapeutic approaches Journal of Investigative Dermatology · 2022
    19. 128 Bimekizumab led to rapid & deep normalisation of molecular signatures associated with PASI sub-components, preceding clinical skin clearance Journal of Investigative Dermatology · 2024
    20. Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy JDDG Journal der Deutschen Dermatologischen Gesellschaft · 2024
    21. Holistic Ayurvedic Management of Psoriasis with special reference to Eka Kustha International Journal of Ayurveda and Pharma Research · 2026
    22. DP10 Scalp disease in dermatomyositis British Journal of Dermatology · 2024
    23. Integrative medicine - combination of conventional medicine and traditional herbal medicine may find its potential applications in the treatment of certain dermatological and endocrine diseases – review of the literature Journal of Education, Health and Sport · 2023
    24. Case Report of a Patient With Psoriasis Vulgaris, Psoriatic Arthritis and Alopecia Universalis Successfully Treated With Tofacitinib and Methotrexate JEADV Clinical Practice · 2025
    25. 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index Journal of Investigative Dermatology · 2019
    26. Targeting the Janus Kinase Family in Autoimmune Skin Diseases Frontiers in Immunology · 2019 · 124 citations
    27. Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures Journal of the American Academy of Dermatology · 2012 · 40 citations
    28. 308-nm Excimer Lamp vs. Combination of 308-nm Excimer Lamp and 10% Liquor Carbonis Detergens in Patients With Scalp Psoriasis: A Randomized, Single-Blinded, Controlled Trial Frontiers in Medicine · 2021 · 8 citations
    29. 465 Multicenter prospective study on the efficacy of narrowband ultraviolet B treatment and its effect on quality of life, anxiety, depression in plaque psoriasis patients Journal of Investigative Dermatology · 2023
    30. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo Clinical and Experimental Dermatology · 2017 · 37 citations